Synklino Employee Directory
Biotechnology ResearchHovedstaden, Denmark11-50 Employees
Synklino is a clinical stage biotechnology company pioneering transformative therapies for solid organ transplantation. Our first-in-class drug candidate, SYN002, is a therapeutic fusion protein designed to eliminate both active and latent CMV infection in donated organs through ex vivo organ perfusion, offering a proactive and life-changing therapy for immunocompromised transplant recipients. With regulatory clearance and funding in place, we are on track to deliver clinical data from kidney transplant recipients through 2026.
1-888-653-2347 
support@leadiq.com 
